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Abstract: Staphylococcus aureus is one of the most relevant opportunistic pathogens involved in
many biofilm-associated diseases, and is a major cause of nosocomial infections, mainly due to the
increasing prevalence of multidrug-resistant strains. Consequently, alternative methods to eradicate
the pathogen are urgent. It has been previously shown that polyvalent staphylococcal kayviruses and
their derived endolysins are excellent candidates for therapy. Here we present the characterization of
a new bacteriophage: vB_SauM-LM12 (LM12). LM12 has a broad host range (>90%; 56 strains tested),
and is active against several MRSA strains. The genome of LM12 is composed of a dsDNA molecule
with 143,625 bp, with average GC content of 30.25% and codes for 227 Coding Sequences (CDSs).
Bioinformatics analysis did not identify any gene encoding virulence factors, toxins, or antibiotic
resistance determinants. Antibiofilm assays have shown that this phage significantly reduced the
number of viable cells (less than one order of magnitude). Moreover, the encoded endolysin also
showed activity against biofilms, with a consistent biomass reduction during prolonged periods of
treatment (of about one order of magnitude). Interestingly, the endolysin was shown to be much
more active against stationary-phase cells and suspended biofilm cells than against intact and scraped
biofilms, suggesting that cellular aggregates protected by the biofilm matrix reduced protein activity.
Both phage LM12 and its endolysin seem to have a strong antimicrobial effect and broad host range
against S. aureus, suggesting their potential to treat S. aureus biofilm infections.
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1. Introduction
Currently, the development of bacterial resistance to antibiotics has become a global concern.
Very recently, the World Health Organization (WHO) published a list of priority pathogens resistant
to antibiotics, encouraging the scientific community and pharmaceutical industries to focus on the
development of new antimicrobials to combat antimicrobial-resistant (AMR) pathogens [1]. In the
referred report, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus
(VISA), and vancomycin-resistant S. aureus (VRSA) were considered of high importance [1].
Antibiotic-resistant S. aureus is well-established in both community and healthcare settings,
being one the most frequently isolated pathogens in hospital-associated infections (HAI) [2].
This microorganism is a resourceful pathogen that can cause a wide range of diseases, from food
poisoning to life-threatening diseases such as pneumonia, infective endocarditis, or sepsis [3].
Recent evidence has revealed that S. aureus infections are one of the main causes of hospital
infections, leading to increasing rates of morbidity and mortality, which ultimately increase health
care costs [4,5]. The severity of S. aureus infections is mostly related to its intrinsic ability to acquire
and express antibiotic-resistance genes. Presently, S. aureus has acquired a resistance to practically
Viruses 2018, 10, 182; doi:10.3390/v10040182 www.mdpi.com/journal/viruses
Viruses 2018, 10, 182 2 of 16
all antibiotics [6]. Moreover, its ability to adhere to host tissues and evade human host defenses,
namely by the formation of thick biofilms, increases the difficulty in treating this pathogen [7]. Indeed,
biofilm cells are described as being more tolerant to antibiotics than planktonic cells, mainly due to the
antibiotics’ difficulty penetrating the complex biofilm matrix [8]. Moreover, the slow growth of biofilm
cells limits therapeutic success, as several antibiotics can only target active cells.
Bacteriophages, also known as phages, are natural bactericidal agents that specifically lyse bacteria.
Due to their bacterial host specificity and bacteriolytic activity against antibiotic-resistant strains,
the use of phage therapy has been suggested as a valuable approach to control numerous pathogenic
bacteria, namely S. aureus. During the last decade, a huge importance has been given to the study
of staphylococcal phages, namely their genomes. Although the majority are temperate siphoviruses,
staphylococcal myoviruses have been described as very promising for therapy purposes [9,10].
Moreover, staphylococcal lytic phages have demonstrated their in-vitro potential as anti-biofilm
agents on food matrices and on clinical models, controlling in-vitro biofilms [11–13].
In addition, phage-encoded cell-wall-degrading enzymes, named endolysins, have been proposed
to be potent antibacterial agents [14]. These peptidoglycan hydrolases evolved to rapidly break down
the bacterial cell wall, thereby allowing the release of phage progeny. When endolysins were expressed
heterologously and added to the cells from the outside, they displayed a high bacteriolytic effect in
Gram-positive cells.
In this study, we report the isolation of a new Kayvirus phage, named vB_SauM-LM12 (LM12).
This phage was characterized morphologically and genomically, revealing suitable properties for
therapy. We also purified and characterized the staphylococcal endolysin E-LM12, derived from the
phage LM12, and demonstrated the former’s efficacy as a valuable anti-biofilm agent.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions
S. aureus collection strains were obtained from American Type Culture Collection (ATCC) and
Spanish Type Culture Collection (CECT). Additional S. aureus clinical isolates were obtained from the
Hospital Strain Collection (Braga, Portugal). To complete the phage and endolysin lytic spectrum,
additional staphylococcal strains, and other Gram-positive species from our collection were used.
This accounts to a total of 39 strains used (Table 1), including 29 S. aureus, 7 non-S. aureus staphylococcal
strains, and one representative of Enterococcus faecalis, Enterococcus faecium, and Listeria monocytogenes.
All strains were grown in Tryptic Soy Broth (TSB, VWR Chemicals, Randor, PA, USA), Tryptic Soy
Agar (TSA; VWR Chemicals) or in TSA soft overlays (TSB with 0.6% agar) at 37 ◦C.
Table 1. Phage vB_SauM-LM12 (LM12) spectrum of activity with efficiency of plating (EOP) and
E-LM12 lytic spectrum. High, moderate, and low efficiency of plating represent >10%, 0.01–9%,
and <0.01%, respectively.
Species Strain Origin AntibioticResistance
Phage
Infectivity EOP
Endolysin
Activity
S. aureus ATCC 25923 Clinical Isolate Unknown + High +
ATCC BAA-976 Tracheal aspirate Unknown + Medium −
CECT 239 Human lesion Unknown + High +
Sa1 Expectoration MRSA + Medium +
Sa2 Expectoration MRSA + Low +
Sa3 Expectoration MRSA LFW 1 N/A 2 +
Sa4 Pus MRSA + Medium +
Sa5 Bronchial aspirate MRSA + High +
Sa6 Expectoration MRSA LFW N/A +
Sa7 Expectoration MRSA + High +
Sa8 Expectoration MRSA + High +
Sa9 Urine MRSA LFW N/A +
Sa10 Skin exudate MRSA + High +
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Table 1. Cont.
Species Strain Origin AntibioticResistance
Phage
Infectivity EOP
Endolysin
Activity
Sa11 Skin exudate MRSA + Medium +
Sa12 Urine MRSA + High +
Sa13 Skin exudate MRSA + Medium +
Sa14 Urine MRSA LFW N/A +
Sa15 Expectoration MRSA + High +
Sa16 Bronchial aspirate MRSA + Medium +
Sa17 Nasal exudate MRSA + LFW +
Sa18 Expectoration MRSA LFW N/A +
Sa19 Expectoration MRSA + High +
Sa20 Urine MRSA + Medium +
Sa21 Urine MRSA + High +
Sa22 Expectoration MRSA + High +
Sa23 Expectoration MRSA + High +
Sa24 Skin exudate MRSA LFW N/A +
Sa25 Expectoration MRSA + High +
Sa26 Expectoration MRSA LFW N/A +
S. epidermidis RP62A Catheter-associated sepsis Unknown LFW N/A −
9142 Blood culture Unknown + Low −
S. haemolyticus SECOM 065A.1 [15] Healthy Skin Unknown − − −
S. equorum SECOM060A [15] Healthy Skin Unknown LFW N/A −
S. capitis SECOM052A [15] Healthy Skin Unknown + High −
S. warneri SECOMF16 [15] Healthy Skin Unknown + Medium −
S. hominis SECOMM11 [15] Healthy Skin Unknown LFW N/A −
Enterococcus faecalis CECT 184 Milk Unknown − − −
Enterococcus faecium CECT 410 Unknown Unknown − − −
Listeria
monocytogenes CECT 5725 Chicken Unknown − − −
1 LFW: Lysis from without; 2 N/A—non available.
2.2. Phage Isolation
Phages were isolated from effluent samples of different wastewater treatment plants (WWTP):
Paradela (Vila Verde), Frossos (Braga). The sample enrichment method was performed to isolate
phages [16]. Briefly, 20 mL of the effluent were mixed with 20 mL double-strength TSB and with 50 µL
of each of the exponentially grown S. aureus strains. The resulting suspensions were incubated at 37 ◦C
and 120 rpm (BIOSAN ES-20/60, Riga, Latvia) over 24 h. Suspensions were further centrifuged (10 min,
10,000× g, 4 ◦C), and the resulting supernatants were filtered through a 0.22-µm PES membrane
(GE Healthcare, Little Chalfont, UK).
The presence of phages was checked by performing spot assays on bacterial lawns. Plates were
further incubated at 37 ◦C, for 16–18 h, and the presence of inhibition halos assessed. When present,
the inhibition halos where submitted to repeated picking, until single-plaque morphology was
observed and ten plaques of each isolated phage were measured and characterized.
2.3. Phage Production
Phage particles were produced using the double agar layer method as described before [17].
Briefly, 100 µL of a phage suspension at 106 PFU·mL−1 was spread on a S. aureus Sa12 lawn, using
a paper strip. After 16–18 h of incubation at 37 ◦C, full lysis was checked. Plates were agitated at
120 rpm in an orbital shaker (BIOSAN PSU-10i) for 24 h at 4 ◦C, with 3 mL of an SM Buffer (100 mM
NaCl, 8 mM MgSO4, 50 mM Tris/HCl (pH 7.5)) to resuspend the phage particles. The liquid phase
was collected and centrifuged (10 min, 10,000× g, 4 ◦C).
Phages were concentrated, as described by Sambrook and Russel [18]. First, the phage lysate was
concentrated with NaCl (5.84% w/v) and PEG 8000 (10% w/v), then purified with chloroform (1:4 v/v).
After filtration through a 0.22-µm PES membrane, the samples were stored at 4 ◦C until further use.
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2.4. Electron Microscopy
Phage particles were sedimented by centrifugation (25,000× g, 60 min, 4 ◦C) using a ScanSpeed
1730R centrifuge (Labogene, Lillerød, Denmark). The pellet was further washed in tap water by
repeating the centrifugation step. Subsequently, phage suspension was deposited on copper grids with
a carbon-coated Formvar carbon film on a 200 square mesh nickel grid, stained with 2% uranyl acetate
(pH 4.0) and examined using a Jeol JEM 1400 transmission electron microscope (TEM) (Tokyo, Japan).
2.5. Lytic Spectra and Efficiency of Plating
The host range specificity and lysis efficiency of the isolated phage was screened against all strains
listed in Table 1. Bacterial lawns were made on TSA plates by adding 100 µL of exponential-phase cell
cultures of each strain. The bacterial lawns were spotted with 10 µL drops of serial 10-fold dilutions of
the phage solution. After 16–18 h incubation at 37 ◦C, results were observed and scored. The relative
efficiency of plating (EOP) was calculated as the ratio between the phage titer (PFU/mL) obtained in
each isolate and the one obtained in the propagating host.
2.6. DNA Isolation, Genome Sequencing, and in Silico Analysis
Phage DNA was extracted essentially as described before [17]. Briefly, purified phages were
treated with 0.016% (v/v) L1 buffer (300 mM NaCl, 100 mM Tris/HCl (pH 7.5), 10 mM EDTA,
0.2 mg BSA mL−1, 20 mg RNase A mL−1 (Sigma, Saint Louis, MO, USA), 6 mg DNase I mL−1 (Sigma))
for 2 h at 37 ◦C, and the enzymes were further thermally inactivated for 30 min at 65 ◦C. Proteins
were further digested with 50 µg proteinase K mL−1, 20 mM EDTA and 1% SDS, for 18 h at 56 ◦C.
This was followed by phenol, phenol:chloroform (1:1, v/v) and chloroform extractions. DNA was then
precipitated with isopropanol and 3 M sodium acetate (pH 4.6), centrifuged (15 min, 7600× g, 4 ◦C),
and the pellet air-dried and resuspended in nuclease-free water (Cleaver Scientific, Rugby, UK).
Afterwards, the phage genome was sequenced with an Illumina MiSeq platform conducted in
Nucleomics Core (VIB, Leuven, Belgium). LM12 DNA was mixed with another non-homologous
phage (at equimolar ratio) and subjected to quality controls using an Agilent Bioanalyzer (Santa Clara,
CA, USA). DNA library preparations were made by a custom kit (Nextera XT sample prep, Illumina,
San Diego, CA, USA) to generate an average insert size of 500 bp. All DNA library preparations were
pooled together and sequenced using 150-bp unpaired reads. After processing, reads were trimmed to
remove adapters, contaminations, or low-quality sequences. Contigs were assembled, with a relatively
homogenous coverage, with the CLC genomics Workbench version 7 (CLC Bio, Aarhus, Denmark),
using the de novo assembly algorithm and manual inspection.
The genome was firstly annotated using MyRAST algorithm [19], and was further manually
inspected for potential alternative start codons or for the presence of non-annotated CDSs using
Geneious 9.1.4 (Biomatters Ltd., Auckland, New Zealand). Functions of the gene products were
searched with BLASTp [20] and Pfam [21] programs (E-value≤ 10−5). The presence of transmembrane
domains was checked using TMHMM [22] and Phobius [18], and membrane proteins were annotated
when both tools were in concordance. Protein parameters (molecular weight and isoelectric point)
were determined using ExPASy Compute pI/Mw [23]. Transfer RNAs (tRNAs) were scanned using
tRNAscan-SE [24] and ARAGORN [18].
Promoter regions were determined using PromoterHunter from the phiSITE database [25] and
checked manually. ARNold [26] was used to predict rho-independent terminators and the energy was
calculated using Mfold [27]. The DNA homology comparisons between phages were conducted with
progressiveMauve [28].
The phylogenetic analysis of homologous phages was performed on Geneious 9.1.4. For phylogenetic
purposes, the LM12 genome was aligned with 27 other staphylococcal phage genomes using the
MAFFT Alignment on Geneious. The resulting alignment was used to build a phylogenetic tree using
a Maximum-Likelihood phylogenetic (PHYML) algorithm with a bootstrapping of 100.
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2.7. Expression Plasmid Construction
Primers containing the restriction cloning sites of NdeI/XhoI (underlined) were designed to
amplify the LM12 putative lysin (forward CCGCCG CATATG GAATTCATGGCTAAGACTCAAGC
AGAAATAAATAAA, and reverse CCGCCG CTCGAG TTAACCTTTGAATACACCCCAGG) by PCR
with Phusion Polymerase (ThermoFisher, Waltham, MA, USA). The PCR product was digested with
proper endonucleases (FastDigest—ThermoFisher) and ligated with T4 DNA ligase (New England
Biolabs, Ipswich, MA, USA), according to the manufacturer’s protocols, into pET28a (Novagen,
Merck Millipore, Burlington, MA, USA), resulting in the plasmid pET28a–LM12 encoding the lysin
with a C-terminal His-tag. The resulting plasmid was propagated and maintained in E. coli TOP10.
The correct insertion of the lysin gene into the plasmid was confirmed by Sanger sequencing (GATC
Biotech, Konstanz, Germany).
2.8. Recombinant Protein Production and Purification
E. coli BL21(DE3) cells transformed with the recombinant plasmid were grown at 37 ◦C in an LB
medium supplemented with the appropriate antibiotic (50 µg/mL of kanamycin), until an OD620nm of
0.550 and recombinant protein expression was induced by IPTG (1 mM final concentration) overnight
at 16 ◦C. The cells were recovered by centrifugation, resuspended in lysis buffer (20 mM Na2H2PO4,
500 mM sodium chloride, 10 mM imidazole, pH 7.4), and disrupted to release the expressed protein.
Cell disruption was accomplished by three thaw-freezing cycles (from −80 ◦C to room temperature)
followed by a 5-min sonication (Cole-Parmer Ultrasonic Processor, Vernon Hills, IL, USA) for 10 cycles
(30 s pulse, 30 s pause) at 40% amplitude. Soluble cell-free extracts were collected by centrifugation,
filtered, and loaded on a 1 mL Ni-NTA agarose stacked in a Polypropylene column (Qiagen, Hilden,
Germany), previously equilibrated with 10 mM imidazole, making use of the protein N-terminal
His-tag. The washing step was performed using protein-dependent imidazole concentrations (lysis
buffer supplemented with 20 mM imidazole in the first wash and 40 mM imidazole in the second) and
elution, carried out with 300 mM imidazole in lysis buffer.
The purified protein was analyzed by SDS-PAGE using a 12% (w/v) acrylamide gel, followed by
BlueSafe staining (NZYTech, Lisbon, Portugal). The eluted protein was concentrated and dialyzed
against 20 mM HEPES pH 8.0 using the centrifugal filters Amicon Ultra—0.5 mL (Merck Millipore)
and stored at 4 ◦C.
2.9. Activity on Planktonic Cells
The activity of E-LM12 lysin against planktonic cells in both exponential and stationary phases
was performed as described before [29]. In brief, to obtain a suspension of stationary phase cells,
S. aureus was grown for 48 h at 37 ◦C and 120 rpm. Cell suspensions were diluted with spent medium
(centrifuged medium used to grow the cells, and to avoid regrowth of the cells) to obtain an optical
density at 600 nm (OD600nm) of approximately 0.4 (~5 × 108 colony forming units (CFU)·mL−1).
Exponentially growing cells were obtained by inoculating 10 mL of fresh TSB with 100 µL of the
overnight grown culture, and allowing bacteria to grow until OD600nm reached approximately 0.4.
Cells were pelleted by centrifugation and further resuspended in 8 µM of endolysin. Samples were
taken at 2 h, 6 h, and 24 h post-contact with the lysin. The number of cultivable cells (CFU·mL−1) was
quantified using the microdrop method (10 µL drops of 10-fold dilutions of the suspension are spotted
on agar medium petri plates and the number of CFUs recorded), and the antibacterial activity assessed
as the relative inactivation in logarithmic units (log10 (N0/Ni); N0 is the number of untreated cells in
the negative control, and Ni is the number of treated cells counted after incubation). Three independent
experiments were performed in triplicate. Control experiments were performed by adding 20 mM
HEPES, pH 8.0 buffer instead of endolysin suspension.
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2.10. Biofilm Formation
Biofilm formation was performed by inoculating one S. aureus colony in TSB (10 mL),
and incubating for 16 h in an orbital shaker (120 rpm, BIOSAN) at 37 ◦C. To establish mature
biofilms, 2 µL of the starter culture were transferred into 96-well polystyrene plates (Orange Scientific,
Braine-l’Alleud, Belgium) containing 198 µL of TSB supplemented with 1% filtered glucose (w/v)
(TSBG). The plates were incubated for 24 h in an orbital shaker incubator (120 rpm, BIOSAN ES-20/60)
at 37 ◦C. Biofilms were washed twice more with saline solution. After scraping, samples were sonicated
for 10 s at 30% amplitude to eliminate clusters [30], and the number of cultivable cells determined
using the microdrop method. Three independent experiments were performed in triplicate.
2.11. Biofilm Challenge
Twenty-four hour biofilms were infected as previously described [29], with some modifications.
Briefly, biofilm supernatants were removed, and the biofilms were washed twice with saline solution.
Thereafter, 200 µL of phage (Multiplicity of infection of 1) or endolysin (8 µM) were added to each
well. Microplates were incubated at 37 ◦C and 120 rpm, and samples were taken at 2 h, 6 h, and 24 h
post-infection. Samples were sonicated for 10 s at 30%, and the number of cultivable cells determined
using the microdrop method. Three independent experiments were performed in triplicate. Control
experiments were performed by adding SM buffer instead of phage suspension, or 20 mM HEPES and
pH 8.0 instead of endolysin.
2.12. Minimal Inhibitory Concentration Assay
A classical microdilution broth method was used to determine E-LM12 minimal inhibitory
concentration (MIC), as previously described [31,32]. All MIC values represent three assays, with three
replicates in each assay.
2.13. Infection of Scraped Biofilm Cells
To assess lysin activity against disrupted biofilms, 24 h biofilms were washed twice with saline
solution, and the biofilm three-dimensional (3D) structure was disturbed by a slight manual scraping.
Biofilm suspension was further challenged with the endolysin, using the conditions described for
biofilm challenge. Control experiments were performed by adding HEPES buffer instead of endolysin
suspension. Three independent experiments were performed in duplicate.
2.14. Infection of Suspended Biofilm Cells
The endolysin activity on biofilm cells was tested by manually scraping double-washed 24 h
biofilms until their full detachment from the surfaces. Samples were homogenized by vortexing,
to allow each matrix to detach from the biofilm cells and be further challenged with the endolysin,
using reaching the conditions described for the biofilm challenge. Control experiments were performed
by adding HEPES buffer instead of endolysin suspension. Three independent experiments were
performed in duplicate.
2.15. Statistical Analysis
The assays were compared using two-way ANOVA and Sidak post-test, using Prism 6 (GraphPad,
La Jolla, CA, USA). Means and standard deviations (SD) were calculated. Differences among conditions
were considered statistically significant when p < 0.01.
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3. Results
3.1. LM12 Is a New S. aureus-Infecting Phage
Twenty-six MRSA clinical strains were used for phage enrichment, using wastewater treatment
plant sewage samples as phage sources. Although no phages were detected in the Frossos effluents,
when using Paradela raw sewage a phage vB_SauM_LM12 (LM12) was isolated, and its plaque
morphology was characterized by clear and uniform small plaques (0.5 mm in diameter) on the host
strain (n = 10). According to TEM micrographs, LM12 belongs to the Myoviridae family (Figure 1).
Phage particles are composed by an icosahedral head, 83 nm in diameter, and a contractile tail of
168 × 20 nm (n = 5). Furthermore, phage particles are composed of a neck, conspicuous transverse tail
striations, a baseplate, and terminal bulbous spikes.
Figure 1. Morphology of LM12. Transmission electron microscopic image of Staphylococcus myovirus
LM12 negatively stained with 2% (w/v) uranyl acetate. Scale bar represents 50 nm.
3.2. LM12 Is a Polyvalent Phage with a Wide Host Lytic Range among Clinical Isolates
A collection of 29 S. aureus isolates, seven other staphylococci, and three strains of other
Gram-positive pathogens were used to determine the host range of LM12 and corresponding EOP
(Table 1). Interestingly, LM12 has a broad spectrum of activity, showing a lytic effect in all S. aureus
strains tested, infecting 22 out of the 29 S. aureus strains tested. Moreover, it shows a lytic effect
against all other Staphylococcus spp. strains, excluding the S. haemolyticus strain tested. Furthermore,
no lysis was observed on non-staphylococcal strains. In some cases, lysis from external events were
observed, as phage haloes were observed with high phage concentrations, but no plaques could
be seen when decreasing the phage titer. This phenomenon was mainly present on non-S. aureus
staphylococcal strains.
Regarding the EOP experiments, in general, LM12 showed high to moderate EOP in the majority
of the strains.
3.3. Antibacterial Assays Show That LM12 Can Inhibit S. aureus Biofilms
Phage infection was performed on Sa12 24-h biofilms, using a Multiplicity of Infection (MOI)
of 1. According to the infection results, Sa12 can significantly decrease the number of viable biofilm
cells about one order of magnitude during the first 6 h of infection (p < 0.01). However, after 24 h,
the biofilm cells might have acquired resistance to the phage, and consequently, the numbers of cells
after 24 h of infection increased (Figure S1).
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3.4. LM12 Genome Is Similar to Kayvirus Genomes
The complete genomic sequence of bacteriophage LM12 was determined and deposited in
GenBank under the accession number MG721208. LM12 has a linear dsDNA genome consisting
of 143,652 bp, with a GC content of 29.3%. Semi-automatic annotation predicted that LM12 encodes 227
proteins, of which 70 have a putative function and 157 are considered hypothetical/novel (Table S1).
LM12 genes are packed tightly, occupying ~90% of the genome. Most predicted gene products exhibit
homology to known proteins of phages belonging to the Kayvirus genus, mostly to Staphylococcus
phages G1, GH15, and P108. Moreover, three tRNA coding for Asp, Phe, and Trp were detected before
the lytic module (gp157), and one tRNA coding for Met was detected between two genes with an
unknown function (gp197A and gp198).
As in other phages of this genus, long-terminal repeats (LTRs) were detected at the genome ends.
Although the exact borders between the LTRs and the rest of phage DNA has not been determined,
the region between the bofl and treA genes was estimated to have 11.5 Kb, which is longer than other
kayviruses [10].
The LM12 genome is organized in functional modules, related to DNA replication and
transcription, DNA packaging, phage morphogenesis, and cell lysis (Figure 2). On the left arm of LM12
genome are located genes encoding for DNA replication, recombination, and modification, namely
nicotinamide phosphoribosyl transferase (gp25) and phosphoribosyl pyrophosphate synthetase (gp27);
however, the majority of the genes found encode for proteins with unknown functions.
Figure 2. Genome overview of the Staphylococcus phage LM12. Genome map with predicted 227
coding sequences (CDSs) numbered and colored (yellow shows hypothetical proteins, blue shows
DNA replication and transcription genes, green represents DNA packaging and phage morphogenesis
genes, and red indicates cells lysis genes) according to their predicted function. Some important CDSs
are highlighted. Above the genome, the nucleotide position in kb is given. The figure was performed
using Geneious 9.1.4.
In the mid-range of the genome are located the majority of genes encoding for proteins
related to DNA replication, recombination, and modification, including DNA polymerase A (gp89),
ribonucleotide reductase (gp94 and gp95), DNA repair recombinase (gp85) and DNA primases/
helicases (gp100, gp106, and gp108). Downstream in this region are found some structural genes,
namely encoding the baseplate proteins (gp114, gp116, and gp117), tail-related proteins (gp115,
gp 121–124, gp131–132), tail fiber proteins (gp109 and gp113), and capsid proteins (gp136 and gp139).
In the beginning of the right arm of the genome, genes encoding DNA packaging proteins,
including portal protein (gp142) and terminase (gp149) are found, followed by the lytic module
composed of a holin (gp158) and endolysin (gp159). Finally, a small group of DNA replication,
recombination, and modification genes, including those encoding the ribonuclease H (gp169),
PhoH-related protein (gp171), nucleoside 2-deoxyribosyltransferase (gp174), and serine/threonine
protein phosphatase (gp200).
Moreover, 26 bacterial-origin promoters and 23 rho-independent terminators were detected.
Whole-genome comparison analysis has shown that LM12 shares >90% identity and >90% coverage
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with the majority of the staphylococcal phages belonging to the Kayvirus genus. When the LM12
genome was aligned with 27 other kayviruses, the presence of four groups was visible on the generated
tree (Figure 3). The group where phage LM12 was present is composed of three other phages, including
IME-SA119 (KR908644), JD007 (NC_019726), and SA5 (JX875065), having 85%, 82%, and 83% identity,
respectively. Moreover, LM12 shows identities <40% with the other 24 phages analyzed. Progressive
Mauve analysis was performed between LM12, IME-SA119, JD007, and SA5 phages, in order to
analyze sequence similarities. Results demonstrated that in general, LM12 is homologous with the
other three phages, showing few noticeable differences (Figure S2). Several hypothetical proteins
(including gp12–14, gp17–18, gp26, gp33, gp43, gp105, gp111, gp145, gp160, and gp198) are encoded
within the more divergent genomic regions. Moreover, differences were observed in terminal repeat
regions of TreA (gp15) and TreU (gp211). Comparing the four genomes, it was also possible to detect
slight differences on the N-terminus of ribonucleotide reductase small subunit (gp94), and on the
C-terminus of the tail morphogenetic protein (gp115).
Figure 3. Phylogenetic tree from LM12 genome and its most closely related phage genomes. The tree
was generated with a Maximum-Likelihood phylogenetic (PHYML) algorithm, with a bootstrapping
of 100. Four groups are indicated (green, orange, purple, and blue), and arrows indicates phage LM12.
The figure was performed using Geneious 9.1.4.
3.5. LM12 Genome Encodes a Modular Lysin with Broad Bactericidal Activity
In silico analysis of LM12 identified gp159 as the endolysin (E-LM12). This protein has a
molecular weight of about 57.74 KDa and a pI of 10.08. This is a 496 amino acid modular protein
composed of a N-terminal cysteine, histidine-dependent amidohydrolase/peptidase (CHAP) domain
(PF05257), an Amidase-2 (PF01510) domain in the middle, and a SRC Homology 3 (SH3) (PF08460)
cell-wall-binding domain on the C-terminus.
BLAST analysis revealed that E-LM12 shows high similarity with the endolysins from several
staphylococcal phages, including Staphylococcus phage phiIPLA-RODI (100% coverage, 98% identity).
After expression in E. coli, the soluble fraction of E-LM12 was purified by nickel affinity
chromatography, via its C-terminal 6× His-tag. Our procedure led to a purified stock concentration
of 120–140 mg/L of protein in the induced E. coli culture. As expected, E-LM12 was active against a
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wide range of staphylococci strains, including MRSA clinical isolates (Table 1). Moreover, the lysin
was unable to lyse other Gram-positive bacteria, such as L. monocytogenes, E. faecium, and E. faecalis.
E-LM12 activity was determined by an MIC assay. The endolysin was able to inhibit S. aureus
Sa12 growth at concentrations of 34.5 ± 10.5 µg·mL−1.
3.6. E-LM12 Has an Anti-Biofilm Effect, Being Able to Lyse Exponential and Stationary Phase Cells
The anti-biofilm potential of the endolysin E-LM12 was assessed (Figure 4a). Two hours after
endolysin addition, the number of viable biofilm cells was reduced by about 1.7 orders of magnitude
(p < 0.01). The reduction decreased slightly after 6 h, when a reduction of about 1.1 orders of magnitude
was detected (p < 0.01). This reduction was maintained after 24 h of infection, which suggests that no
endolysin resistance was acquired by biofilm cells.
The influence of the biofilm’s 3D structure on lysin activity was assessed by scraping the biofilm,
in order to disturb its complex 3D structure (Figure 4b). Results have shown that E-LM12 reduced
the number of viable cells by about 1.3 orders of magnitude in all time points tested (p < 0.01),
suggesting that there are no significant differences on endolysin efficacy against intact or physically
disturbed biofilms.
Figure 4. Endolysin E-LM12 activity against S. aureus biofilms, using 8 µM (a) intact biofilms;
(b) scraped biofilms. Data was assessed by CFU counting, and the values represent the mean
(plus or minus) of three independent experiments performed in duplicate. Statistical differences
(p < 0.01) between the control biofilms and the LM12-treated biofilms (*) were determined by two-way
repeated-measures analysis of variance (ANOVA) with a Sidak post-test.
To get a deeper understanding of endolysin–cell interactions, the protein efficacy was tested
against exponential, stationary, and biofilm cells.
E-LM12 demonstrated a high bactericidal activity against exponential-phase cells, reducing the
number of viable cells by approximately 4.5 and 4.8 orders of magnitude after 2 h and 6 h, respectively
(p < 0.01) (Figure 5a). Moreover, this endolysin was very active against stationary-phase cells, as it
was able to reduce the cell numbers by 3.2 orders of magnitude, which was maintained for six hours
(p < 0.01) (Figure 5b).
To understand the influence of the biofilm matrix in lysin efficacy, biofilms were disrupted and
collected into a homogeneous suspension of biofilm cells (Figure 5c). E-LM12 was active against
biofilm cells, reducing them by 2.7 orders of magnitude in the first 2 h, which was slightly increased to
three orders of magnitude after 6 h of infection (p < 0.01).
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Figure 5. Endolysin E-LM12 activity against 24 h S. aureus planktonic cells, using 8 µM (a) exponential
phase cells, (b) stationary phase cells, and (c) biofilm suspended cells. Data was assessed by CFU
counting, and the values represent the mean (plus or minus) of three independent experiments
performed in duplicate. Statistical differences (p < 0.01) between control biofilms and LM12-treated
biofilms (*) were determined by two-way repeated-measures analysis of variance (ANOVA) with a
Sidak post-test.
4. Discussion
Nowadays, the emergence of multidrug-resistant strains is a main concern [33]. In fact, the WHO
recently suggested that the scientific community and pharma industries develop new antimicrobials to
combat multi-resistant pathogens, namely the MRSA, VISA, and VRSA strains [1]. The use of lytic
bacteriophages and their cell-wall-degrading enzymes (endolysins) have been catching the attention of
both researchers and industry as possible tools to combat AMR pathogens. To achieve that, we aimed
to isolate phages with lytic activity against S. aureus.
As a general strategy, we searched for lytic bacteriophages from environmental sewage waters,
using a set of different clinical MRSA isolates to be combined in the sewage enrichment. When Paradela
(Vila Verde) effluents were used, it was possible to isolate a S. aureus phage. The selected phage was
analyzed by TEM, and images suggested that it belongs to the Kayvirus genus [34], formerly known
as Twortlikevirus [35]. The phage was named vB_SauM_LM12, according to Kropinski et al.’s [36]
recommendations. After sequencing, LM12 was included in the Class III group, as defined by
Kwan [37], due to its myovirus morphology, genome size between 140–150 Kbp, and proper gene
organization. General genome features—such as G + C content, number of genes, tRNA genes, and
genome organization—related LM12 with phage K, which is one of the well-studied S. aureus strictly
lytic phages [38]. Comparative genomics studies have suggested that LM12 belongs to the Kayvirus
genus, clustering with members of the Staphylococcus virus JD7 species. The modular feature of the
phage genome is stressed by the presence of S. aureus σ70 promoters and rho-independent terminators.
One particularity of the LM12 genome is the absence of introns, which are very common among
Staphylococcus myoviruses [10]. A similar phenomenon was described for Staphylococcus phage GH15,
where no introns were detected in its genes for encoding critical enzymatic functions [39]. Recently,
Abatangelo et al. [40], suggested that this event might indicate intron loss. Overall, the high genomic
similarities and the gene organization suggest genome mosaicism among staphylococcal myoviruses,
which is in accordance with the model of modular evolution among phages. In this model, horizontal
gene transfer events may lead to new genetic combinations [41].
Usually, Staphylococcus myoviruses are polyvalent phages with strictly virulent behavior,
displaying a broad host range. For those reasons, they are considered the most promising phages from
a therapeutic point of view [35]. The lytic potential of Kayviruses against S. aureus has been shown in
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different settings [11–13,42]. LM12 was no exception, as it showed a polyvalent behavior lysing all
S. aureus tested strains, regardless their origin. Usually, viruses of this family adsorb to staphylococcal
cells, using the anionic backbone of the cell wall teichoic acid (WTA) as a receptor [43]. More recently,
it was shown that myovirusΦSA012 possesses at least two receptor binding proteins (RBP), one binding
to theα-GlcNAc in WTAs and the other expected to bind the WTA backbone [44]. BothΦSA012 proteins
have homologous proteins in LM12 genome, namely gp109 and gp111. The presence of more than one
RBP can justify the broad spectra of Kayviruses.
As more than 60% of all infections are caused by biofilms [45], the anti-biofilm potential of LM12
was tested. Although several studies focus on biofilm biomass reduction [46,47], the purpose of this
study was to assess LM12’s direct effect on biofilm cells. During the first 6 h of infection, 90% of the
biofilm cells were killed. However, a regrowth was observed at 24 h of infection, which might be
related with the emergence of phage-resistant mutants, something already observed when biofilms
are challenged by a single phage [48]. Even so, given the broad lytic spectra of LM12 and its quick
anti-biofilm potential, the inclusion of LM12 in a cocktail with phages with complementary host
ranges could constitute a valuable weapon against AMR Staphylococcus, and prevent the emergence of
phage-resistant phenotypes [49].
Besides phages, phage-derived endolysins have been widely studied against S. aureus. Although
some endolysins are effective against S. aureus biofilms [50–52], few studies are detailed in lysin–biofilm
interactions. The endolysin from phage LM12 was cloned, heterologously expressed, and purified.
The purified enzyme was named E-LM12, and showed activity against all S. aureus strains tested,
namely MRSA clinical isolates. Curiously, no effect was observed against non-S. aureus staphylococci.
The amino acid sequence of E-LM12 is very conserved, being closely related to several staphylococcal
endolysins [53]. Therefore, it was not surprising that the MIC of E-LM12 was comparable to previous
studies with other lysins, namely LysK [30,54]. In addition, it was demonstrated that E-LM12
could disrupt biofilms, causing greater than 90% reduction of the biofilm cells, at least up to 24 h.
In opposition to the phage killing assays, no increase on the biofilm biomass was detected at 24 h of
infection, suggesting that there were no resistance mechanisms developed by the biofilm cells against
the endolysins. This absence of resistance to phage’s endolysins is in accordance to what has been
described [55].
Although the reduction obtained on biofilms was significant, it was considered relevant to
understand the influence of the physiological state of the cells with E-LM12 activity, as well as the
influence of the complex 3D structure of the biofilm. As biofilms are generally created by bacterial
cells that are in a wide range of physiological states, E-LM12 was tested against exponential- and late
stationary-phase cells. Although the endolysin E-LM12 has shown to be highly active against both
types of cells, higher reductions were observed in exponential-phase cells. S. aureus stationary-phase
cells have been shown to have thicker cell walls, with non-uniformly thickened septa, in comparison to
exponential-phase cells [56]. Furthermore, the fact that around 12% of the stems in the peptidoglycan
do not have pentaglycine bridges attached [56] might justify the lower activity of the studied endolysin
on stationary-phase cells, as the CHAP domain cleaves interpeptide bridges exclusively [57], and the
SH3 binding domain recognizes pentaglycine cross bridges in the peptidoglycan [58]. The fact that
E-LM12 could infect biofilm cells within the same orders of magnitude as stationary-phase cells
suggested that lysin efficacy was not highly affected by cell physiology. A similar phenomenon was
detected in the artificially-modified lysin, Art-240, against streptococci [59].
The biofilm matrix can act as a barrier, per se, conferring protection to the biofilm cells—for
example, against antibiotics [8]. As the studied endolysin was active against cells with different
morphological/physiological states, E-LM12 was tested against biofilms whose architecture was
mechanically disrupted (scraped biofilms). Surprisingly, the endolysin activity was not improved
by this light disruption, suggesting that the reminiscent cellular aggregates are still protected by the
biofilm matrix, and that this matrix interferes with LM12 activity.
Viruses 2018, 10, 182 13 of 16
Taken together, phage LM12 and its endolysin seem to have a strong and broad host range
effect against S. aureus. Their anti-biofilm potential could be increased by using a combination
of different phages and endolysins [60], or by using them in combination with matrix-disrupting
chemicals [61]. In conclusion, phage LM12, and mainly its endolysin E-LM12, present strong
potential in the development of new products to control the highly pathogenic and antibiotic-resistant
Staphylococcus aureus.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/10/4/182/s1,
Table S1: Features of LM12 predicted coding sequences (CDSs). For each CDS, the transcription start and stop
position and the coding strand is given. At protein level, the corresponding gene product size, molecular weight,
and pI, as well as the homolog predicted function, homologs, and E-values and motifs are shown; Figure S1:
Phage LM12 infection on 24 h S. aureus biofilms, using a multiplicity of infection (MOI) 1. Data was assessed by
colony forming units (CFU) counting, and the values represent the mean (plus or minus) of three independent
experiments performed in duplicate. Statistical differences (p < 0.01) between control biofilms and LM12-treated
biofilms (*) were determined by two-way repeated-measures analysis of variance (ANOVA) with a Sidak post-test;
Figure S2: Multiple genome alignment of Staphylococcus phage LM12 with closest homologs. The figure was
performed using Geneious 9.1.4.
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